FDA approves AstraZeneca’s Imfinzi for limited-stage small cell lung cancer, cutting the risk of death by 27% in the ADRIATIC trial. Imfinzi shows median overall survival of 55.9 months versus ...

(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) announced Thursday that the U.S. Food and Drug Administration has approved Imfinzi (durvalumab) to treat adult patients with limited ...

AstraZeneca’s (AZN) Imfinzi has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer, LS-SCLC whose disease has not progressed following ...

The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with limited-stage small cell lung cancer, the health regulator said on Wednesday.

With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 43% of AstraZeneca‘s total revenues) rose 18% in the second quarter of 2025, generating $6.3 ...

WILMINGTON, Del. -- (BUSINESS WIRE)-- AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC ...

On Friday, AstraZeneca Plc AZN released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as a perioperative treatment for patients with resectable Stage II-IVA ...

AstraZeneca strives to redefine cancer care and help transform outcomes for patients with IMFINZI as a monotherapy and in combination with IMJUDO as well as other novel immunotherapies and modalities.

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Friday that Imfinzi (durvalumab) has been approved in the European Union for the treatment of adult patients with resectable ...